Awardee OrganizationSTATE UNIVERSITY NEW YORK STONY BROOK
Description
Abstract Text
Adenylate cyclase is the mediator of the action of numerous hormones and
neurotransmitters and it is central to the control of metabolism and
function in probably all tissues. Its activity is modulated by numerous
agents of physiological and biochemical interest, including calcium and
some bacterial toxins, and consequently a better understanding of the
control of cellular cAMP metabolism is dependent on an understanding of the
regulation of adenylate cyclase. As with numerous other enzymes important
to cell regulation, calcium activation of a brain adenylate cyclase is
mediated by calmodulin, though the basis of the sensitivity of the brain
cyclase to calmodulin is not known. There is only an emerging picture of
the number of components of the hormone receptor-adenylate cyclase system,
without any clear understanding of the mechanisms of their interaction
which regulate cyclase activity.
The proposed research focuses on the mechanisms of calmodulin-induced
activation of adenylate cyclase and will ascertain whether it: a) involves
the participation of the stimulatory and inhibitory guanine nucleotide
regulatory components; b) involves other unidentified components, unique to
the calmodulin-sensitive enzyme; c) resides in unique properties of the
catalytic unit of the calmodulin-sensitive enzyme; or d) involves a
combination of these possibilities. The two principal approaches will be
to purify the Ca2+/calmodulin-sensitive adenylate cyclase and to identify
with labelled calmodulin and crosslinking agents calmodulin binding
proteins associated with this enzyme. The potential role of Ns and/or Ni
on calmodulin activation of the cyclase will be determined through indirect
and direct assessments and through reconstitution studies. Given that
divalent cation has an established role in the regulation of adenylate
cyclase activity, character of their involvement in calmodulin-activation
of the brain enzyme will be determined.
Polyclonal and/or monoclonal antibodies will be prepared against the
cyclase catalytic unit and/or the associated calmodulin-binding protein.
These will be used: a) to develop immunopurification adsorbants; and b)\to
clarify questions of localization of this form of cyclase or of the
associated calmodulin-binding protein.
In the narrow sense, the studies will aid our understanding of how
individual agents change adenylate cyclase activity, but in the broader
sense will give insights into the integration of cell regulatory processes
involving both cAMP and calcium.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
DUNS Number
804878247
UEI
M746VC6XMNH9
Project Start Date
01-September-1986
Project End Date
31-August-1990
Budget Start Date
01-September-1986
Budget End Date
31-August-1987
Project Funding Information for 1986
Total Funding
$129,226
Direct Costs
$86,856
Indirect Costs
$42,370
Year
Funding IC
FY Total Cost by IC
1986
National Institute of Diabetes and Digestive and Kidney Diseases
$129,226
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7R01DK038828-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7R01DK038828-01
Patents
No Patents information available for 7R01DK038828-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7R01DK038828-01
Clinical Studies
No Clinical Studies information available for 7R01DK038828-01
News and More
Related News Releases
No news release information available for 7R01DK038828-01
History
No Historical information available for 7R01DK038828-01
Similar Projects
No Similar Projects information available for 7R01DK038828-01